Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 15:13:1107.
doi: 10.3389/fnins.2019.01107. eCollection 2019.

Adoptive Transfer of Regulatory T Cells as a Promising Immunotherapy for the Treatment of Multiple Sclerosis

Samuel S Duffy  1 , Brooke A Keating  1 , Gila Moalem-Taylor  1
Affiliations

Adoptive Transfer of Regulatory T Cells as a Promising Immunotherapy for the Treatment of Multiple Sclerosis

Samuel S Duffy et al. Front Neurosci. .
No abstract available

Keywords: adoptive cell transfer; experimental autoimmune encephalomyelitis; immunotherapy; multiple sclerosis; regulatory T cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Potential therapeutic action of Treg cell therapy. In the inflamed CNS, Treg cells can mediate immunosuppression and reduce inflammation through various mechanisms and help tissue repair by promoting myelin regeneration. Mechanisms involved in reducing neuroinflammation are: (i) secretion of anti-inflammatory cytokines produced by Treg cells (TGF-β, IL-10, and IL-35); (ii) metabolic disruption ameliorating effector T (Teff) cell function; (iii) cytolysis of Teff cells; and (iv) antigen presenting cell (APC) inactivation. Additionally, Treg cells may promote oligodendrocyte differentiation and remyelination in the damaged CNS through the production of CCN3, a growth regulatory protein.
See this image and copyright information in PMC

References

    1. Baecher-Allan C., Kaskow B. J., Weiner H. L. (2018). Multiple sclerosis: mechanisms and immunotherapy. Neuron 97, 742–768. 10.1016/j.neuron.2018.01.021 - DOI - PubMed
    1. Beers D. R., Zhao W., Wang J., Zhang X., Wen S., Neal D., et al. . (2017). ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight 2:e89530. 10.1172/jci.insight.89530 - DOI - PMC - PubMed
    1. Bluestone J. A., Buckner J. H., Fitch M., Gitelman S. E., Gupta S., Hellerstein M. K., et al. . (2015). Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 7:315ra189. 10.1126/scitranslmed.aad4134 - DOI - PMC - PubMed
    1. Bluestone J. A., Tang Q. (2018). Treg cells-the next frontier of cell therapy. Science 362, 154–155. 10.1126/science.aau2688 - DOI - PubMed
    1. Brunstein C. G., Miller J. S., McKenna D. H., Hippen K. L., DeFor T. E., Sumstad D., et al. . (2016). Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood 127, 1044–1051. 10.1182/blood-2015-06-653667 - DOI - PMC - PubMed

LinkOut - more resources